27 July 2026
CRISM Therapeutics Corporation
("CRISM", "CRISM Therapeutics" or the "Company")
Results of Shareholder Analysis
CRISM Therapeutics Corporation (AIM: CRTX), a UK clinical-stage drug delivery company focused on the localised and sustained delivery of chemotherapy drugs, announces that following the completion of an independent third-party shareholder register analysis, that as at 30 June 2026, the Company is aware of the following significant shareholders, being those with an interest in 3% or more of the ordinary share capital of the Company ("Ordinary Shares"):
|
Shareholder |
No. of Ordinary Shares |
% interest in the ordinary share capital of the Company |
|
Miton UK Smaller Companies Fund |
7,500,000 |
9.47% |
|
Mr Andrew Webb |
7,297,190 |
9.22% |
|
Dr Christopher McConville |
4,992,033 |
6.30% |
|
Mr Brian Murray |
4,908,700 |
6.20% |
|
Mr David Lawton |
4,012,220 |
5.07% |
|
Zeus Dynamic Opportunities Fund |
3,150,000 |
3.98% |
|
Hobart Capital Markets LLP |
2,830,000 |
3.57% |
|
Mr John Rylands |
2,388,892 |
3.02% |
-Ends-
Enquiries:
|
Company |
Nomad and Broker |
Financial PR |
|
CRISM Therapeutics Corporation |
S.P. Angel Corporate Finance LLP |
Burson Buchanan |
|
Andrew Webb, Executive Chairman Chris McConville, CSO |
David Hignell Vadim Alexandre Adam Cowl |
Henry Harrison Topham Jamie Hooper CRISM@buchanancomms.co.uk |
|
via Burson Buchanan |
+44 (0) 20 3470 0470 |
+44 (0) 20 7466 5000 |
About CRISM Therapeutics Corporation
CRISM Therapeutics Corporation has developed an innovative drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs.
ChemoSeed, CRISM's lead product, can be implanted directly into the tumour or the resection margin following the removal of a tumour. This directs that therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour tissue or cover the entire resection margin. In the case of treating glioblastoma, ChemoSeeds can be implanted during surgery thereby bypassing the blood brain barrier, which prevents other treatments from being able to reach the tumour and be effective.
For more information please visit: https://www.crismtherapeutics.com/